Has Gnanagurdasan Prakasam received payments from drug or device companies?

Yes. Drug and device makers reported $804,764 in general payments to Gnanagurdasan Prakasam across 1,576 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gnanagurdasan Prakasam did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gnanagurdasan Prakasam come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gnanagurdasan Prakasam

Pediatric Endocrinology · Sacramento, CANPI 1871586065

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $547,427 of the $804,764 with a category attached, or 68.0%. 41 manufacturers reported payments, led by Novo Nordisk at 40.5% of the total. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$804,764in general payments, 2019–2025

Across 1,576 payments — averaging $510.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$326K
Ultragenyx Pharmaceutical Inc.$164K
AstraZeneca$92K
Neurocrine Biosciences, Inc.$56K
AbbVie$46K
Kyowa Kirin, Inc.$44K
plus $77K from 35 others

$3,007,668in research payments, 2019–2025

Across 1,673 payments — averaging $1797.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Dexcom, Inc.$974K
Eli Lilly$593K
Medtronic$408K
Pfizer$335K
Mannkind Corporation$284K
Novo Nordisk AS$157K
plus $258K from 7 others

What the payments were for

Consulting fees$100,09512%
Speaking & faculty fees$547,42768%
Travel & lodging$134,44317%
Food & beverage$22,2313%
Education$5080%
Gifts$590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	390	$325,764
Ultragenyx Pharmaceutical Inc.	251	$164,185
AstraZeneca	159	$91,937
Neurocrine Biosciences, Inc.	75	$56,266
AbbVie	222	$45,635
Kyowa Kirin, Inc.	88	$44,030
Lilly USA, LLC	79	$41,196
Sanofi-aventis U.S. LLC	22	$10,095
Ascendis Pharma Endocrinology Inc	24	$8,045
Ferring Pharmaceuticals Inc.	19	$5,101
Dexcom, Inc.	8	$3,194
Roche Diabetes Care, Inc.	1	$2,900
Mannkind Corporation	35	$2,065
Abbott	37	$788
Biomarin Pharmaceutical Inc.	12	$558
Tandem Diabetes Care, Inc.	19	$481
Companion Medical, Inc.	16	$316
Pfizer	17	$309
Tolmar Pharmaceuticals, Inc.	19	$280
Medtronic(2 entities)	13	$236
Zealand Pharma US, Inc.	11	$200
Azurity Pharmaceuticals, Inc.	8	$176
Vistapharm, Inc.	8	$150
Tolmar, Inc.	5	$132
BD	5	$126
Xeris Pharmaceuticals, Inc.	6	$92
Soleno Therapeutics, Inc.	3	$73
Insulet Corporation	4	$68
Lifescan, Inc.	4	$65
Ipsen Biopharmaceuticals, Inc	2	$48
Amgen(2 entities)	2	$38
Amphastar Pharmaceuticals, Inc.	2	$38
Krystal Biotech Inc	1	$31
IBSA Pharma Inc.	2	$28
Embecta Corp.	1	$21
Endo USA, Inc.	1	$20
Ascensia Diabetes Care US Inc.	1	$19
Nevro Corp.	1	$17
Arbor Pharmaceuticals, Inc.	1	$15
Endo Pharmaceuticals Inc.	1	$14
Regeneron Healthcare Solutions, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Norditropin$160,293
CRYSVITA$142,012
Sogroya$122,755
CRENESSITY$53,706
Lupron Depot$43,523
Strensiq$41,361
BAQSIMI$24,400
Cryvista$17,288
LYUMJEV$16,225
Ozempic$9,811
TZIELD$9,617
Tresiba$9,394
SKYTROFA$7,482
RYBELSUS$4,879
ZOMACTON$4,559
DEXCOM CGM$3,045
Accu-Chek Inform II Instrument with RF card$2,900
AFREZZA$1,231
t:slim X2 Insulin Pump with Control-IQ$134

How this compares

$804,764 in reported general payments places this provider in the 95th percentile of 168 pediatric endocrinology providers in California.

See all pediatric endocrinology providers in California →

Other pediatric endocrinology in Sacramento

Ulhas NadgirSacramento$14K
Niyati SkariaSacramento$6K
Swati ElchuriVentura$210K
Karen KleinSan Diego$195K
Francine KaufmanLos Angeles$184K
Lynda PolgreenOrange$167K
Kevin KaisermanWest Covina$150K
Amrit BhangooLong Beach$140K
Mitchell GeffnerLos Angeles$129K
Stephen GitelmanSan Francisco$105K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →